Valid for Submission
T46.2X5A is a billable code used to specify a medical diagnosis of adverse effect of other antidysrhythmic drugs, initial encounter. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code T46.2X5A might also be used to specify conditions or terms like adenosine adverse reaction, amiodarone adverse reaction, amiodarone-induced corneal epithelial deposit, antiarrhythmic drug adverse reaction, bretylium adverse reaction, cirrhosis of liver caused by amiodarone, etc
The code T46.2X5A describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.
| ICD-10: | T46.2X5A |
| Short Description: | Adverse effect of other antidysrhythmic drugs, init encntr |
| Long Description: | Adverse effect of other antidysrhythmic drugs, initial encounter |
Replaced Code
This code was replaced in the 2020 ICD-10 code set with the code(s) listed below. The National Center for Health Statistics (NCHS) has published an update to the ICD-10-CM diagnosis codes which became effective October 1, 2019. This code was replaced for the FY 2020 (October 1, 2019 - September 30, 2020).
- K59.03 - Drug induced constipation
Code Edits
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
- Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual’s health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.
Synonyms
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Adenosine adverse reaction
- Amiodarone adverse reaction
- Amiodarone-induced corneal epithelial deposit
- Antiarrhythmic drug adverse reaction
- Bretylium adverse reaction
- Cirrhosis of liver caused by amiodarone
- Class I antiarrhythmic adverse reaction
- Class II antiarrhythmic adverse reaction
- Class III antiarrhythmic adverse reaction
- Class IV antiarrhythmic adverse reaction
- Corneal pigmentations and deposits
- Disopyramide adverse reaction
- Drug-induced cirrhosis of liver
- Drug-induced corneal epithlelial deposit
- Drug-induced disorder of cornea
- Drug-induced lupus erythematosus
- Drug-induced lupus erythematosus due to procainamide
- Drug-induced pericarditis
- Drug-induced thyroiditis
- Esophagitis medicamentosa
- Flecainide adverse reaction
- Hyperthyroidism secondary to amiodarone
- Iatrogenic thyrotoxicosis
- Mexiletine adverse reaction
- Moracizine adverse reaction
- Pill esophagitis
- Pill esophagitis due to quinidine
- Procainamide adverse reaction
- Procainamide-induced pericarditis
- Propafenone adverse reaction
- Quinidine adverse reaction
- Quinidine toxicity by EKG
- Thyroiditis caused by amiodarone
- Tocainide adverse reaction
Convert T46.2X5A to ICD-9
- 995.29 - Adv eff med/biol NEC/NOS (Combination Flag)
- E942.0 - Adv eff card rhyth regul (Combination Flag)
Code Classification
Code History
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
(First year ICD-10-CM implemented into the HIPAA code set) - FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020